Show simple item record

dc.contributor.authorTan, W
dc.contributor.authorWilner, K
dc.contributor.authorLanzalone, S
dc.contributor.authorPolli, A
dc.contributor.authorZierhut, M
dc.contributor.authorNickens, D
dc.contributor.authorO'Byrne, K
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorShaw, A
dc.contributor.authorSalgia, R
dc.contributor.authorJaime, J
dc.contributor.authorKim, D
dc.date.accessioned2016-04-25T11:32:26Zen
dc.date.available2016-04-25T11:32:26Zen
dc.date.issued2015-08-02en
dc.identifier.citationAbstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC) 2015, 75 (15 Supplement):CT117 Cancer Resen
dc.identifier.issn0008-5472en
dc.identifier.issn1538-7445en
dc.identifier.doi10.1158/1538-7445.AM2015-CT117en
dc.identifier.urihttp://hdl.handle.net/10541/606889en
dc.language.isoenen
dc.relation.urlhttp://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2015-CT117en
dc.rightsArchived with thanks to Cancer Researchen
dc.titleAbstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC)en
dc.typeMeetings and Proceedingsen
dc.identifier.journalCancer Researchen


This item appears in the following Collection(s)

Show simple item record